Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46


Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer.

Caruana E, Foucher Y, Tessier P, Frenel JS, Classe JM, Dantan E.

Breast Cancer Res Treat. 2019 Jan 2. doi: 10.1007/s10549-018-05107-6. [Epub ahead of print]


Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.

Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M.

Expert Opin Drug Metab Toxicol. 2018 Dec 21. doi: 10.1080/17425255.2019.1559816. [Epub ahead of print]


miR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating Biomarker.

Nadaradjane A, Briand J, Bougras-Cartron G, Disdero V, Vallette FM, Frenel JS, Cartron PF.

Mol Ther Nucleic Acids. 2018 Dec 7;13:642-650. doi: 10.1016/j.omtn.2018.09.007. Epub 2018 Sep 13.


Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma.

Raoul JL, Faivre S, Frenel JS, Rimassa L.

Ann Oncol. 2019 Jan 1;30(1):6-8. doi: 10.1093/annonc/mdy471. No abstract available.


Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.

Cottu P, D'Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Callens C, Gentien D, Lemonnier J, Vincent-Salomon A, Delaloge S.

Ann Oncol. 2018 Dec 1;29(12):2334-2340. doi: 10.1093/annonc/mdy448.


The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners.

Congard A, Christophe V, Duprez C, Baudry AS, Antoine P, Lesur A, Loustalot C, Guillemet C, Leclercq M, Segura C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, Vanlemmens L.

J Psychosoc Oncol. 2018 Oct 8:1-19. doi: 10.1080/07347332.2018.1479326. [Epub ahead of print]


Emerging PARP inhibitors for treating breast cancer.

Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M.

Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29. Review.


An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.

Robert M, Frenel JS, Bourbouloux E, Rigaud DB, Patsouris A, Augereau P, Gourmelon C, Campone M.

Drugs. 2018 Sep;78(13):1353-1362. doi: 10.1007/s40265-018-0972-9.


5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.

Ploquin A, Pistilli B, Tresch E, Frenel JS, Lerebours F, Lesur A, Loustalot C, Bachelot T, Provansal M, Ferrero JM, Coussy F, Debled M, Kerbrat P, Vinceneux A, Allouache D, Morvan F, Dalenc F, Guiu S, Rouzier R, Vanlemmens L.

Eur J Cancer. 2018 May;95:30-37. doi: 10.1016/j.ejca.2018.02.030. Epub 2018 Apr 3.


Global cancer control: responding to the growing burden, rising costs and inequalities in access.

Prager GW, Braga S, Bystricky B, Qvortrup C, Criscitiello C, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A.

ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.


Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.

du Rusquec P, Palpacuer C, Campion L, Patsouris A, Augereau P, Gourmelon C, Robert M, Dumas L, Caroline F, Campone M, Frenel JS.

Breast Cancer Res Treat. 2018 Apr;168(2):559-566. doi: 10.1007/s10549-017-4623-8. Epub 2017 Dec 15.


Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses.

Duprez C, Vanlemmens L, Untas A, Antoine P, Lesur A, Loustalot C, Guillemet C, Leclercq M, Segura C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, Christophe V.

Future Oncol. 2017 Dec;13(29):2667-2680. doi: 10.2217/fon-2017-0264. Epub 2017 Dec 1.


Efficacy of buparlisib in treating breast cancer.

Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M.

Expert Opin Pharmacother. 2017 Dec;18(18):2007-2016. doi: 10.1080/14656566.2017.1410139. Epub 2017 Dec 1.


Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A.

J Clin Oncol. 2017 Dec 20;35(36):4035-4041. doi: 10.1200/JCO.2017.74.5471. Epub 2017 Nov 2.


Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.

Augereau P, Patsouris A, Bourbouloux E, Gourmelon C, Abadie Lacourtoisie S, Berton Rigaud D, Soulié P, Frenel JS, Campone M.

Ther Adv Med Oncol. 2017 May;9(5):335-346. doi: 10.1177/1758834017693195. Epub 2017 Mar 14. Review.


Olaparib for the treatment of breast cancer.

Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M.

Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21. Review.


Vinflunine for the treatment of breast cancer.

Gourmelon C, Bourien H, Augereau P, Patsouris A, Frenel JS, Campone M.

Expert Opin Pharmacother. 2016 Sep;17(13):1817-23. doi: 10.1080/14656566.2016.1217991. Epub 2016 Aug 10. Review.


Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study.

Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, Bennouna J.

Clin Colorectal Cancer. 2016 Dec;15(4):e165-e174. doi: 10.1016/j.clcc.2016.04.009. Epub 2016 May 7.


Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.

Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, Bachelot T, D'Hondt V, Darlix A, Firmin N, Romieu G, Thezenas S, Dalenc F.

Breast Cancer Res Treat. 2016 Jun;157(2):307-318. doi: 10.1007/s10549-016-3828-6. Epub 2016 May 11.


[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].

Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, Bennouna J.

Bull Cancer. 2016 Jun;103(6):541-51. doi: 10.1016/j.bulcan.2016.03.007. Epub 2016 May 5. French.


Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME.

Clin Cancer Res. 2016 Oct 1;22(19):4797-4806. Epub 2016 May 3.


[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].

Frenel JS, Bally O, Bourbouloux E, Berton-Rigaud D, Campone M, Bachelot T, Heudel PÉ.

Bull Cancer. 2016 May;103(5):507-10. doi: 10.1016/j.bulcan.2016.02.005. Epub 2016 Mar 15. Review. French. No abstract available.


An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.

Awada A, Campone M, Varga A, Aftimos P, Frenel JS, Bahleda R, Gombos A, Bourbouloux E, Soria JC.

Anticancer Drugs. 2016 Apr;27(4):342-8. doi: 10.1097/CAD.0000000000000336.


Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas.

Alentorn A, Dehais C, Ducray F, Carpentier C, Mokhtari K, Figarella-Branger D, Chinot O, Cohen-Moyal E, Ramirez C, Loiseau H, Elouahdani-Hamdi S, Beauchesne P, Langlois O, Desenclos C, Guillamo JS, Dam-Hieu P, Ghiringhelli F, Colin P, Godard J, Parker F, Dhermain F, Carpentier AF, Frenel JS, Menei P, Bauchet L, Faillot T, Fesneau M, Fontaine D, Motuo-Fotso MJ, Vauleon E, Gaultier C, Le Guerinel C, Gueye EM, Noel G, Desse N, Durando X, Barrascout E, Wager M, Ricard D, Carpiuc I, Delattre JY, Idbaih A; POLA Network.

Neurology. 2015 Oct 13;85(15):1325-31. doi: 10.1212/WNL.0000000000002014. Epub 2015 Sep 18.


Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.

Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS.

Clin Cancer Res. 2015 Oct 15;21(20):4586-96. doi: 10.1158/1078-0432.CCR-15-0584. Epub 2015 Jun 17.


[Unusual antenatal gestational choriocarcinoma].

Tardif C, Nowak C, Sagan C, Frenel JS, Philippe HJ.

Gynecol Obstet Fertil. 2014 Oct;42(10):725-8. doi: 10.1016/j.gyobfe.2014.07.033. Epub 2014 Sep 18. French.


Tumor clone dynamics in lethal prostate cancer.

Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, S de Bono J, Demichelis F, Attard G.

Sci Transl Med. 2014 Sep 17;6(254):254ra125. doi: 10.1126/scitranslmed.3009448.


Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M, Mervoyer A, Martin S, Denis MG, Campone M.

J Neurooncol. 2013 Aug;114(1):85-91. doi: 10.1007/s11060-013-1152-0. Epub 2013 May 17.


bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses.

Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G, Campone M.

Database (Oxford). 2013 Jan 15;2013:bas060. doi: 10.1093/database/bas060. Print 2013.


Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series.

Rodrigues MJ, Peron J, Frénel JS, Vano YA, Wassermann J, Debled M, Picaud F, Albiges L, Vincent-Salomon A, Cottu PH.

Ann Oncol. 2013 Apr;24(4):916-24. doi: 10.1093/annonc/mds536. Epub 2012 Oct 26.


Pulse oximetry and high-dose vasopressors: a comparison between forehead reflectance and finger transmission sensors.

Nesseler N, Frénel JV, Launey Y, Morcet J, Mallédant Y, Seguin P.

Intensive Care Med. 2012 Oct;38(10):1718-22. Epub 2012 Aug 7.


[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].

Campone M, Frenel JS, André F, Bachelot T, Juin P.

Bull Cancer. 2012 Jun;99(6):665-72. doi: 10.1684/bdc.2012.1591. Review. French.


Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.

Loussouarn D, Le Loupp AG, Frenel JS, Leclair F, Von Deimling A, Aumont M, Martin S, Campone M, Denis MG.

Int J Oncol. 2012 Jun;40(6):2058-62. doi: 10.3892/ijo.2012.1404. Epub 2012 Mar 16.


What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

Gourmelon C, Frenel JS, Campone M.

Expert Rev Anticancer Ther. 2012 Feb;12(2):195-201. doi: 10.1586/era.11.167. Review.


Eribulin mesylate for the treatment of late-stage breast cancer.

Gourmelon C, Frenel JS, Campone M.

Expert Opin Pharmacother. 2011 Dec;12(18):2883-90. doi: 10.1517/14656566.2011.637490. Epub 2011 Nov 17. Review.


Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.

Classe JM, Jaffre I, Frenel JS, Bordes V, Dejode M, Dravet F, Ferron G, Marchal F, Rigaud DB, Loussouarn D, Campion L.

Eur J Surg Oncol. 2011 Nov;37(11):971-7. doi: 10.1016/j.ejso.2011.08.138. Epub 2011 Sep 25.


NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.

Redjimi N, Duperrier-Amouriaux K, Raimbaud I, Luescher I, Dojcinovic D, Classe JM, Berton-Rigaud D, Frenel JS, Bourbouloux E, Valmori D, Ayyoub M.

PLoS One. 2011;6(7):e22845. doi: 10.1371/journal.pone.0022845. Epub 2011 Jul 29.


[Her2 positive breast cancer: practices].

Campone M, Berton-Rigaud D, Bourbouloux E, Sophie S, Zanetti A, Frenel JS.

Bull Cancer. 2011 Feb;98(2):154-63. Review. French.


[The role of interval surgery in the treatment's strategy of advanced ovarian cancer].

Jaffré I, Bordes V, Dejode M, Dravet F, Frénel JS, Berton-Rigaud D, Classe JM.

Bull Cancer. 2011 Jan;98(1):37-42. doi: 10.1684/bdc.2010.1290. Review. French.


[Chemotherapy for early breast cancer: practices in 2010].

Frénel JS, Campone M.

J Gynecol Obstet Biol Reprod (Paris). 2010 Dec;39(8 Suppl):F79-84. doi: 10.1016/j.jgyn.2010.10.005. Epub 2010 Nov 5. Review. French.


Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients.

Frenel JS, Leux C, Pouplin L, Ferron G, Berton Rigaud D, Bourbouloux E, Dravet F, Jaffre I, Classe JM.

J Surg Oncol. 2011 Jan 1;103(1):10-6. doi: 10.1002/jso.21732.


Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: a decline since 2003.

Fontenoy AM, Leux C, Delacour-Billon S, Allioux C, Frenel JS, Campone M, Molinié F.

Cancer Epidemiol. 2010 Jun;34(3):238-43. doi: 10.1016/j.canep.2010.03.007. Epub 2010 Apr 20.


[Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer].

Classe JM, Muller M, Frenel JS, Berton Rigaud D, Ferron G, Jaffré I, Gladieff L.

J Gynecol Obstet Biol Reprod (Paris). 2010 May;39(3):183-90. doi: 10.1016/j.jgyn.2009.12.007. Epub 2010 Jan 29. Review. French.


Lapatinib in metastatic breast cancer.

Frenel JS, Bourbouloux E, Berton-Rigaud D, Sadot-Lebouvier S, Zanetti A, Campone M.

Womens Health (Lond). 2009 Nov;5(6):603-12. doi: 10.2217/whe.09.54. Review.


[Prognostic and predictive factors for gliomas in adults].

Frenel JS, Botti M, Loussouarn D, Campone M.

Bull Cancer. 2009 Apr;96(4):357-67. doi: 10.1684/bdc.2008.0776. Review. French.


Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas.

Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, Pioud-Martigny R, Berton-Rigaud D, Bourbouloux E, Mosnier JF, Bataille FR, Campone M.

Br J Cancer. 2008 Jun 17;98(12):1993-8. doi: 10.1038/sj.bjc.6604400. Epub 2008 Jun 10.

Supplemental Content

Loading ...
Support Center